Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 8/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8321907 | 1.00 | CSNK1D (0.43) | CSNK1DCSNK1EKCNH2PRKACAPRKACG | |
| SCHEMBL280628 | 1.00 | CSNK1D (0.43) | CSNK1DCSNK1EKCNH2PRKACAPRKACG | |
| Hydrochloric Acid SCHEMBL28500586 | 0.98 | CSNK1D (0.43) | CSNK1DCSNK1EKCNH2PRKACAPRKACG | |
| Hydrochloric Acid SCHEMBL28214300 | 0.98 | CSNK1D (0.43) | CSNK1DCSNK1EKCNH2PRKACAPRKACG | |
| SCHEMBL2944138 | 0.81 | CHRNA7 (0.47) | PRKACAPRKACGPRKACBPRCPCTSK | |
| SCHEMBL3399522 | 0.81 | PRKACA (0.47) | CSNK1DCSNK1EKCNH2PRKACAPRKACG | |
| SCHEMBL14839620 | 0.81 | PRKACA (0.41) | PRKACAPRKACGPRKACBACVR1CTSK | |
| SCHEMBL22589151 | 0.81 | CHRNA7 (0.47) | PRKACAPRKACGPRKACBPRCPCTSK | |
| SCHEMBL21717791 | 0.81 | MAPT (0.44) | KCNH2PRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL5545595 | 0.81 | MAPT (0.44) | CSNK1DCSNK1EKCNH2PRKACAPRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105837526-B | A kind of preparation method of the alcohol of 4 benzyl 3 (4 fluorophenyl) morpholine of the important synthetic intermediate of aprepitant (2S, 3R) 2 | 浙江工业大学 | 2018-02-27 | — | — | CN | claimed |
| CN-103214426-A | Production method of aprepitant morpholine key intermediate body or aprepitant morpholine salt | SHANGHAI KY PHARMACEUTICAL CO LTD | 2013-07-24 | — | — | CN | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | CONVERGENE, LLC | 2025-12-16 | — | — | US | disclosed |
| WO-2025060911-A1 | SUBSTITUTED PYRIDOTRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都奥睿药业有限公司 | 2025-03-27 | — | — | WO | disclosed |
| EP-4424379-A2 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3958867-B1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20220259200-A1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEROF | CONVERGENE, LLC | 2022-08-18 | — | — | US | disclosed |
| CN-114786675-A | Small molecule bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114478631-A | Preparation of fosaprepitant dimeglumine | 江苏慧聚药业股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-0942734-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| US-5786367-A | OXYGEN SCAVENGERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-28 | — | — | US | disclosed |
| WO-1998024439-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| EP-0719258-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996002508-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
| CN-1022685-C | Hydrofluorene derivatives | OTSUKA PHARMA CO LTD (JP) | 1993-11-10 | — | — | CN | disclosed |
| US-5017724-A | Antihypoxic, CNS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0267024-B1 | HYDROFLUORENE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| EP-0267024-A2 | Hydrofluorene derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | BRD4, BRPF3, BICRA | CSNK1D 1687/4885CSNK1E 1103/4885KCNH2 4706/4885 |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | CSNK1D 1427/4885CSNK1E 2305/4885KCNH2 4122/4885 |
| US-20220259200-A1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEROF | BRPF3, BRDT, BRD3 | CSNK1D 657/4885CSNK1E 364/4885KCNH2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.